Published in J Urol on January 01, 2006
Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol (2009) 4.07
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol (2007) 3.65
Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications. BJU Int (2013) 2.10
Management of complications of prostate cancer treatment. CA Cancer J Clin (2008) 1.91
Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol (2010) 1.66
Treatment and prevention of bone complications from prostate cancer. Bone (2010) 1.60
Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes (2007) 1.49
Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer. J Urol (2011) 1.27
Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Curr Opin Endocrinol Diabetes Obes (2010) 1.09
Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol (2008) 1.08
Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med (2009) 1.03
Denosumab in patients with cancer-a surgical strike against the osteoclast. Nat Rev Clin Oncol (2012) 1.02
Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX. Osteoporos Int (2009) 1.00
Fracture risk in men with prostate cancer: a population-based study. J Bone Miner Res (2011) 1.00
Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club. Osteoporos Int (2007) 0.99
Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy. J Gen Intern Med (2007) 0.98
Zoledronic acid in the management of metastatic bone disease. Ther Clin Risk Manag (2008) 0.97
Bone health and prostate cancer. Prostate Cancer Prostatic Dis (2009) 0.97
A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma. BMC Urol (2010) 0.95
Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer. J Clin Oncol (2012) 0.95
Mapping the prescriptiome to fractures in men--a national analysis of prescription history and fracture risk. Osteoporos Int (2008) 0.93
Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States. Pharmacoepidemiol Drug Saf (2011) 0.90
Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer. BJU Int (2008) 0.88
Correlates of trabecular and cortical volumetric BMD in men of African ancestry. J Bone Miner Res (2009) 0.87
Treatment-related osteoporosis in men with prostate cancer. Clin Cancer Res (2006) 0.87
Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer. J Urol (2012) 0.87
Estrogenic side effects of androgen deprivation therapy. Rev Urol (2007) 0.87
Contemporary therapeutic approaches targeting bone complications in prostate cancer. Clin Genitourin Cancer (2010) 0.85
Cancer treatment-related bone disease. Crit Rev Eukaryot Gene Expr (2009) 0.84
Management of complications of androgen deprivation therapy in the older man. Crit Rev Oncol Hematol (2008) 0.83
Natural history and correlates of hip BMD loss with aging in men of African ancestry: the Tobago Bone Health Study. J Bone Miner Res (2009) 0.83
Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues. Indian J Urol (2009) 0.82
Androgen deprivation therapy toxicity and management for men receiving radiation therapy. Prostate Cancer (2012) 0.81
Regulation of postnatal trabecular bone formation by the osteoblast endothelin A receptor. J Bone Miner Res (2011) 0.81
Bone-targeted agents: preventing skeletal complications in prostate cancer. Urol Clin North Am (2012) 0.80
Managing bone loss and bone metastases in prostate cancer patients: a focus on bisphosphonate therapy. Rev Urol (2008) 0.80
Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand. BMC Cancer (2015) 0.79
A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy. Curr Oncol (2011) 0.79
The current practice of screening, prevention, and treatment of androgen-deprivation-therapy induced osteoporosis in patients with prostate cancer. J Oncol (2012) 0.78
Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. Prostate Cancer Prostatic Dis (2012) 0.77
Bone resorption facilitates osteoblastic bone metastatic colonization by cooperation of insulin-like growth factor and hypoxia. Cancer Sci (2014) 0.77
RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis. J Osteoporos (2011) 0.76
Optimal delivery of male breast cancer follow-up care: improving outcomes. Breast Cancer (Dove Med Press) (2015) 0.75
Efficacy and safety of high-dose-rate brachytherapy of single implant with two fractions combined with external beam radiotherapy for hormone-naïve localized prostate cancer. Cancers (Basel) (2011) 0.75
Risk stratification in the hormonal treatment of patients with prostate cancer. Ther Adv Med Oncol (2009) 0.75
Male Hypogonadism and Osteoporosis: The Effects, Clinical Consequences, and Treatment of Testosterone Deficiency in Bone Health. Int J Endocrinol (2017) 0.75
Cancer: ADT and acute kidney injury-causal or casual relationship? Nat Rev Endocrinol (2013) 0.75
[Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer]. Wien Med Wochenschr (2012) 0.75
Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol (2005) 2.87
Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease. Cancer (2013) 2.10
Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med (2010) 1.75
Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia (2007) 1.70
The relationship between technology availability and health care spending. Health Aff (Millwood) (2004) 1.65
Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension (2012) 1.65
Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer (2004) 1.64
Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalization. Neurology (2012) 1.62
The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD (2010) 1.59
Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics. Med Oncol (2011) 1.55
Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia. Cancer (2009) 1.54
Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin. Transfusion (2009) 1.53
Removal of opioid/acetaminophen combination prescription pain medications: assessing the evidence for hepatotoxicity and consequences of removal of these medications. Pain Med (2010) 1.51
The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology (2004) 1.47
Incremental direct and indirect costs of untreated vasomotor symptoms. Menopause (2015) 1.45
The economic impact of pre-dialysis epoetin alpha on health care and work loss costs in chronic kidney disease: an employer's perspective. Dis Manag (2008) 1.38
Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study. Epilepsia (2008) 1.32
Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol (2006) 1.28
Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective. J Manag Care Pharm (2009) 1.25
Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer (2006) 1.20
Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. BJU Int (2009) 1.17
Red blood cell transfusions and the risk of acute respiratory distress syndrome among the critically ill: a cohort study. Crit Care (2007) 1.14
The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol (2008) 1.13
Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia. J Natl Compr Canc Netw (2005) 1.06
Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting. Curr Med Res Opin (2008) 1.04
Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause (2011) 1.03
Multivariable confounding adjustment in distributed data networks without sharing of patient-level data. Pharmacoepidemiol Drug Saf (2013) 0.99
Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices. Transfusion (2009) 0.99
Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther (2012) 0.98
Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol (2008) 0.95
Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma. Ann Allergy Asthma Immunol (2012) 0.95
Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism. Patient (2013) 0.94
Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs. Pediatr Blood Cancer (2013) 0.94
Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy. BMC Cancer (2011) 0.92
Impact of chronic hand dermatitis on quality of life, work productivity, activity impairment, and medical costs. J Am Acad Dermatol (2006) 0.91
Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries. Curr Med Res Opin (2009) 0.91
Evaluating minimal clinically important differences for the acne-specific quality of life questionnaire. Pharmacoeconomics (2003) 0.91
Medical costs of untreated anemia in elderly patients with predialysis chronic kidney disease. J Am Soc Nephrol (2006) 0.90
Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy. Epilepsy Behav (2011) 0.90
Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes. Appl Health Econ Health Policy (2014) 0.90
Cost burden and treatment patterns associated with management of heavy menstrual bleeding. J Womens Health (Larchmt) (2012) 0.89
Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review. Support Care Cancer (2008) 0.89
Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. BMC Psychiatry (2013) 0.88
Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. J Thorac Oncol (2006) 0.88
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review. Int J Oncol (2013) 0.87
Costs associated with cardiovascular events in patients with hypertension in US managed care settings. J Am Soc Hypertens (2010) 0.87
Lifetime costs to Medicare of providing care to patients with chronic lymphocytic leukemia. Leuk Lymphoma (2012) 0.86
All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries. J Manag Care Pharm (2012) 0.86
Clinical outcomes, quality of life, and costs associated with implantation of vagus nerve stimulation therapy in pediatric patients with drug-resistant epilepsy. Eur J Paediatr Neurol (2012) 0.86
Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting. Curr Med Res Opin (2015) 0.85
Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA. J Ophthalmic Inflamm Infect (2013) 0.85
The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease. Value Health (2008) 0.84
Systematic literature review of the costs of pregnancy in the US. Pharmacoeconomics (2013) 0.84
Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia. Curr Med Res Opin (2014) 0.84
Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation? Curr Med Res Opin (2013) 0.84
Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database. J Med Econ (2009) 0.83
Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers. J Neurol Sci (2013) 0.83
Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer. Breast Cancer Res Treat (2006) 0.82
Costs, quality of life and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: a review of the literature. Expert Opin Pharmacother (2008) 0.82
Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics. J Med Econ (2013) 0.82
Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Am J Manag Care (2006) 0.82
Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review. J Cancer Res Ther (2010) 0.81
The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer (2007) 0.81
Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population. J Med Econ (2011) 0.81
Dose and cost comparison of erythropoietic agents in the inpatient hospital setting. Am J Health Syst Pharm (2007) 0.80
Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations. Curr Med Res Opin (2006) 0.80
A survey-based assessment of the prevalence and severity of chronic hand dermatitis in a managed care organization. Cutis (2006) 0.80
Burden of schizophrenia on selected comorbidity costs. Expert Rev Pharmacoecon Outcomes Res (2014) 0.80
Economic burden associated with the use of generic antiepileptic drugs in the United States. Epilepsy Behav (2010) 0.79
Comparative antibiotic failure rates in the treatment of community-acquired pneumonia: Results from a claims analysis. Adv Ther (2010) 0.78
The direct and indirect cost burden of atopic dermatitis: an employer-payer perspective. Manag Care Interface (2007) 0.78
Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation? Curr Med Res Opin (2014) 0.78
Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy. Menopause (2016) 0.78
Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective. Pharmacoeconomics (2006) 0.77
Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil: a retrospective, parallel-cohort, hypothesis-generating study. Drugs Aging (2010) 0.77
Current management of anemia in critically ill patients: analysis of a database of 139 hospitals. Am J Ther (2008) 0.77
Association of self-monitoring of blood glucose use on glycated hemoglobin and weight in newly diagnosed, insulin-naïve adult patients with type 2 diabetes. J Diabetes Sci Technol (2013) 0.77
A comparison of therapy continuation rates of different hormone replacement agents: a 9-month retrospective, longitudinal analysis of pharmacy claims among new users. Menopause (2003) 0.77
Actual versus predicted first-year utilization patterns of teriparatide in patients with employer-sponsored health insurance. Curr Med Res Opin (2007) 0.77
Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis. J Med Econ (2015) 0.77
Rates of hospitalization among patients with deep vein thrombosis before and after the introduction of rivaroxaban. Hosp Pract (1995) (2015) 0.77
Multicenter COMPACT study of COMplications in patients with sickle cell disease and utilization of iron chelation therapy. Curr Med Res Opin (2014) 0.77
Psychometric validation of the Patient Symptom Assessment in Lung Cancer instrument for small cell lung cancer. Curr Med Res Opin (2007) 0.77
Symptom assessment in relapsed small cell lung cancer: cross-validation of the patient symptom assessment in lung cancer instrument. J Thorac Oncol (2008) 0.77
All-cause and disease-related health care costs associated with recurrent venous thromboembolism. Thromb Haemost (2013) 0.76
Patient and Caregiver Burden Associated With Fragile X Syndrome in the United States. Am J Intellect Dev Disabil (2015) 0.76
Pulse pressure and stroke risk: development and validation of a new stroke risk model. Curr Med Res Opin (2014) 0.76
The economic impact of epoetin alfa therapy on delaying time to dialysis in elderly patients with chronic kidney disease. Dis Manag (2007) 0.75
Medicaid spending on contraceptive coverage and pregnancy-related care. Reprod Health (2014) 0.75
Is there a difference in the cost-effectiveness of erythropoietic therapies for the treatment of anemia in patients receiving HCV combination therapy? Hepatology (2007) 0.75
Hospital length of stay of nonvalvular atrial fibrillation patients who were administered Rivaroxaban versus Warfarin with and without pretreatment parenteral anticoagulants therapies. Hosp Pract (1995) (2014) 0.75
Cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen. Ann Pharmacother (2008) 0.75
Economic simulation of canagliflozin and sitagliptin treatment outcomes in patients with type 2 diabetes mellitus with inadequate glycemic control. J Med Econ (2014) 0.75
Concomitant asthma medication use in patients receiving omalizumab: results from three large insurance claims databases. J Asthma (2011) 0.75
Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study. Horm Mol Biol Clin Investig (2016) 0.75